BET proteins bind acetylated histone lysine residues, leading to recruitment of P-TEFb via its BRD4 domain to sites of active transcription of genes such as MYC. The prototypical BRD2/4 inhibitor, JQ-1 has been shown to decrease MYC expression in other tumor indications [26, 27]. Here, BRD4 is linked to neoplasm.